Answers are grounded in this paper and cite their sources.
Reviews periorbital soft tissue changes in thyroid eye disease and evaluates targeted therapies, suggesting receptor inhibition can reverse facial disfigurement.
Nabipour I. Clinical endocrinology in the Islamic civilization in Iran. Int J Endocrlnol Metab. 2003;1:43–5. Google Scholar Williams DL. A history of Graves and St. John’s. Eye. 2018;33:174–5. https://www.nature.com/articles/s41433-018-0267-02018332 Available at [Accessed October 17, 2021]. Article Google Scholar Bartalena L, Fatourechi V Extrathyroidal manifestations of Graves’ disease: A 2014 update. J Endocrinol Invest. 2014;8:691–700. Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005;6:295–309. Article Google Scholar Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–38. Article CAS Google Scholar Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012;26:273–9. Article Google Scholar Chin YH, Ng CH, Lee MH, Koh JWH, Kiew J, Yang SP, et al. Prevalence of thyroid eye disease in Graves’ disease: a meta-analysis and systematic review. Clin Endocrinol. 2020;93:363–74. Anon. Involvement of the Eyebrow Fat Pad in Graves’ Orbitopathy: Ophthalmic Plastic & Reconstructive Surgery. Available at: https://journals.lww.com/op-rs/Abstract/1994/06000/Involvement_of_the_Eyebrow_Fat_Pad_in_Graves_.2.aspx [Accessed October, 2021]. Regensburg NI, Kok PHB, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM, et al. A new and validated CT-based method for the calculation of orbital Soft tissue volumes. Investig Ophthalmol Vis Sci. 2008;49:1758–62. Article Google Scholar Papageorgiou KI, Hwang CJ, Chang SHH, Jarullazada I, Chokron Garneau H, Ang MJ, et al. Thyroid-associated periorbitopathy: Eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy. Arch Ophthalmol. 2012;130:319–28. Article Google Scholar Hwang CJ, Khadavi NM, Papageorgiou K, Said J, Chong K, Lee D, et al. Histopathology of brow fat in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg. 2012;28:27–9. Article Google Scholar Choudhary MM, Zhang KR, Johnson S, Hwang CJ, Chon BH, Perry JD Temporal fat pad volume in patients with thyroid eye disease. Ophthal Plast Reconstr Surg. 2020;36:194–7. Savar LM, Menghani RM, Chong KK, Garneau HC, Goldberg RA. Eyebrow tissue expansion: an underappreciated entity in thyroid-associated orbitopathy. Arch Ophthalmol. 2012;130:1566–9. Article Google Scholar Kim BJ, Kazim M. Prominent premalar and cheek swelling: a sign of thyroid-associated orbitopathy. Plast Reconstr Surg. 2006;22:457–60. https://pubmed.ncbi.nlm.nih.gov/17117102/ . Available at [Accessed October 17, 2021]. Article CAS Google Scholar Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181:4397–405. Article CAS Google Scholar Ugradar S, Shi L, Wang Y, Mester T, Yang H, Douglas RS. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye 2021;35:2607–12. Smith TJ, Hoa N. Immunoglobulins from patients with graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076–80. Article CAS Google Scholar Jain AP, Gellada N, Ugradar S, Kumar A, Kahaly G, Douglas R. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol. 2020. Ugradar S, Wang Y, Mester T, Kahaly GJ, Douglas R Improvement of asymmetric thyroid eye disease with teprotumumab. Br J Ophthalmol. 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/33579690/ [Accessed October, 2021]. Ugradar S, Braun J, Wang Y, Zimmerman E, Douglas RS. Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab. Plast Reconstr Surg Glob Open. 2021;9:e3809 https://pubmed.ncbi.nlm.nih.gov/34549003/ . Available at [Accessed October 14, 2021]. Article Google Scholar Park JJ, Sullivan TJ, Mortimer RH, Wagenaar M, Perry-Keene DA. Assessing quality of life in Australian patients with Graves’ ophthalmopathy. Br J Ophthalmol. 2004;88:75–78. Article CAS Google Scholar Wickwar S, McBain HB, Ezra DG, Hirani SP, Rose GE, Newman SP. What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review. Thyroid. 2014;24:1407–18. Article CAS Google Scholar Ferløv-Schwensen C, Brix TH, Hegedüs L. Death by suicide in Graves’ disease and graves’ orbitopathy: a nationwide danish register study. Thyroid. 2017;27:1475–80. Article Google Scholar Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82:773–9. Article CAS Google Scholar Farid M, Roch-Levecq AC, Levi L, Brody BL, Granet DB, Kikkawa DO. Psychological disturbance in Graves ophthalmopathy. Arch Ophthalmol. 2005;123:491–6. Article Google Scholar Download references
No takes yet. Share an insight, caveat, or question.
Ugradar et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: